









Markets
/
Stocks
/
nasdaq-edsa
/

Edesa Biotech Inc

EDSA

2.470USD

+0.170+7.39%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

17.35MMarket Cap

LossP/E TTM



Edesa Biotech Inc

2.470

+0.170+7.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

147 / 506

Overall Ranking

256 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.333

Target Price

+349.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.

Undervalued

The company’s latest PE is -1.99, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.04M shares, increasing 19.86% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 15.86K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.94, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.94

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.85, which is -31.36% below the recent high of -1.27 and 10.43% above the recent low of -1.66.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 147/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Edesa Biotech Inc is 9.00, with a high of 17.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.333

Target Price

+349.28%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Edesa Biotech Inc

EDSA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.64, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.48 and the support level at 2.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.64

Change

0.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.021

Neutral

RSI(14)

56.872

Neutral

STOCH(KDJ)(9,3,3)

55.161

Buy

ATR(14)

0.085

Low Volatility

CCI(14)

-20.514

Neutral

Williams %R

26.087

Buy

TRIX(12,20)

0.224

Sell

StochRSI(14)

86.503

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.404

Buy

MA10

2.412

Buy

MA20

2.417

Buy

MA50

2.328

Buy

MA100

2.189

Buy

MA200

2.161

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 71.71%, representing a quarter-over-quarter increase of 13.91%. The largest institutional shareholder is The Vanguard, holding a total of 15.86K shares, representing 0.23% of shares outstanding, with 50.73% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nijhawan (Pardeep)

1.20M

+0.64%

Rubric Capital Management LP

687.50K

Velan Capital Investment Management LP

687.50K

Nantahala Capital Management, LLC

625.00K

Pardeep Nijhawan Medicine Professional Corporation

341.70K

-5.24%

Brooks (Michael J Ph.D.)

224.87K

+1172.68%

Weiler (Peter John)

65.00K

Marshall (Patrick)

53.13K

+26.11%

Commonwealth Financial Network

50.00K

Digestive Health Clinic Inc.

32.01K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.